Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

被引:22
|
作者
Iaffaldano, Pietro [1 ]
Lucisano, Giuseppe [1 ,2 ]
Patti, Francesco [3 ]
Morra, Vincenzo Brescia [4 ]
De Luca, Giovanna [5 ]
Lugaresi, Alessandra [6 ,7 ]
Zaffaroni, Mauro [8 ]
Inglese, Matilde [9 ]
Salemi, Giuseppe [10 ]
Cocco, Eleonora [11 ]
Conte, Antonella [12 ,13 ]
Ferraro, Diana [14 ]
Galgani, Simonetta [15 ]
Bergamaschi, Roberto [16 ]
Pozzilli, Carlo [17 ]
Salvetti, Marco [13 ,18 ]
Lus, Giacomo [19 ]
Rovaris, Marco [20 ]
Maniscalco, Giorgia Teresa [21 ]
Logullo, Francesco Ottavio [22 ]
Paolicelli, Damiano [1 ]
Achille, Mariaclara [1 ]
Marrazzo, Giuseppina [23 ]
Lovato, Valeria [23 ]
Comi, Giancarlo [24 ]
Filippi, Massimo [24 ]
Amato, Maria Pia [25 ,26 ]
Trojano, Maria [1 ]
机构
[1] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Piazza G Cesare 11, I-70124 Bari, Italy
[2] Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[3] Univ Catania, GF Ingrassia, Dipartimento Sci Med & Chirurg & Tecnol Avanzate, Sez Neurosci,Ctr Sclerosi Multipla, Catania, Italy
[4] Univ Naples Federico II, Multiple Sclerosis Clin Care & Res Ctr, Dept Neurosci NSRO, Naples, Italy
[5] Univ G DAnnunzio, Policlin SS Annunziata, Ctr Sclerosi Multipla, Clin Neurol, Chieti, Italy
[6] IRCCS, Ist Sci Neurol Bologna, Riabilitaz Sclerosi Multipla, Bologna, Italy
[7] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy
[8] S Antonio Abate Hosp, Multiple Sclerosis Ctr, Gallarate, Italy
[9] IRCCS, Osped Policlin San Martino, Dipartimento Neurosci Riabilitaz Oftalmol Genet E, Genoa, Italy
[10] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy
[11] Univ Cagliari, Ctr Sclerosi Multipla, ATS Sardegna, Dept Med Sci & Publ Hlth, Cagliari, Italy
[12] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy
[13] IRCCS, Ist Neurol Mediterraneo INM Neuromed, Pozzilli, Italy
[14] Univ Modena & Reggio Emilia, Nuovo Osped Civile S Agostino Estense, Dept Biosci, Neurol Unit, Modena, Italy
[15] Azienda Osped S Camillo Forlanini, Ctr Sclerosi Multipla, Rome, Italy
[16] IRCCS, Mondino Fdn, Pavia, Italy
[17] Sapienza Univ, S Andrea Hosp, Multiple Sclerosis Ctr, Dept Human Neurosci, Rome, Italy
[18] Sapienza Univ, S Andrea Hosp, CENTERS Ctr Neurol Terapie Sperimentali, Rome, Italy
[19] Univ Naples 2, Div Neurol 2, Multiple Sclerosis Ctr, Dept Clin & Expt Med, Caserta, Italy
[20] IRCCS, Fdn Don Carlo Gnocchi ONLUS, Multiple Sclerosis Ctr, Milan, Italy
[21] Osped A Cardarelli, Ctr Reg SM, Naples, Italy
[22] UOC Neurol Macerata, Area Vasta 3, Macerata, Italy
[23] Roche SpA, Monza, Italy
[24] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurol, Milan, Italy
[25] Univ Florence, Dept Neurofarba, Florence, Italy
[26] IRCCS, Fdn Don Carlo Gnocchi, Florence, Italy
关键词
Multiple sclerosis; secondary progressive; disease registry; big data; prognosis; data-driven algorithm;
D O I
10.1177/1352458520974366
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: No uniform criteria for a sensitive identification of the transition from relapsing-remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients (n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA (n = 2343, 12.1%) were older, more disabled and with a faster progression to severe disability (p < 0.0001), than those identified by the ND (n = 3868, 20.0%). In both groups, the most consistent risk factors (p < 0.05) for SPMS were a multifocal onset, an age at onset >40 years, higher baseline EDSS score and a higher number of relapses; the most consistent protective factor was the disease-modifying therapy (DMT) exposure. DMT exposure during SP did not impact the risk of reaching irreversible EDSS 6.0. Conclusion: A DDA definition of SPMS identifies more aggressive progressive patients. DMT exposure reduces the risk of SPMS conversion, but it does not prevent the disability accumulation after the SP transition.
引用
收藏
页码:430 / 438
页数:9
相关论文
共 50 条
  • [1] Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
    Hedstrom, Anna Karin
    Hillert, Jan
    Olsson, Tomas
    Alfredsson, Lars
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (10): : 1096 - 1102
  • [2] DMD effectiveness in relapsing-onset multiple sclerosis tends to decline with disability progression and years since onset
    Brown, M. G.
    Skedgel, C.
    Kirby, S.
    Fisk, J. D.
    Sketris, I. S.
    Bhan, V.
    Murray, T. J.
    MULTIPLE SCLEROSIS, 2007, 13 : S45 - S45
  • [3] "Hidden" symptoms drive progression independent of relapse activity in relapsing-onset multiple sclerosis patients
    Portaccio, E.
    Fonderico, M.
    Aprea, M. G.
    Masciulli, C.
    Cecconi, E.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Confalonieri, P.
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G. T.
    Morra, V. Brescia
    Salemi, G.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 166 - 167
  • [4] Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
    Li, Ying
    Saul, Alice
    Taylor, Bruce
    Ponsonby, Anne-Louise
    Simpson-Yap, Steve
    Blizzard, Leigh
    Broadley, Simon
    Lechner-Scott, Jeannette
    Lucas, Robyn
    Dear, Keith
    Ponsonby, Anne-Louise
    Dwyer, Terry
    van der Mei, Ingrid
    Blizzard, Leigh
    Simpson-Yap, Steve
    Taylor, Bruce
    Broadley, Simon
    Kilpatrick, Trevor
    Williams, David
    Lechner-Scott, Jeanette
    Shaw, Cameron
    Chapman, Caron
    Coulthard, Alan
    Pender, Michael
    Valery, Patricia
    Karabudak, Rana
    Patti, Francesco
    Eichau, Sara
    Onofrj, Marco
    Ozakbas, Serkan
    Horakova, Dana
    Kubala Havrdova, Eva
    Grand'Maison, Francois
    Alroughani, Raed
    Gerlach, Oliver
    Amato, Maria Pia
    Altintas, Ayse
    Girard, Marc
    Duquette, Pierre
    Blanco, Yolanda
    Ramo-Tello, Cristina
    Laureys, Guy
    Kalincik, Tomas
    Khoury, Samia J.
    Shaygannejad, Vahid
    Etemadifar, Masoud
    Singhal, Bhim
    Mrabet, Saloua
    Foschi, Matteo
    Habek, Mario
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 472 - 485
  • [5] Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
    Ying Li
    Alice Saul
    Bruce Taylor
    Anne-Louise Ponsonby
    Steve Simpson-Yap
    Leigh Blizzard
    Simon Broadley
    Jeannette Lechner-Scott
    Rana Karabudak
    Francesco Patti
    Sara Eichau
    Marco Onofrj
    Serkan Ozakbas
    Dana Horakova
    Eva Kubala Havrdova
    Francois Grand’Maison
    Raed Alroughani
    Oliver Gerlach
    Maria Pia Amato
    Ayse Altintas
    Marc Girard
    Pierre Duquette
    Yolanda Blanco
    Cristina Ramo-Tello
    Guy Laureys
    Tomas Kalincik
    Samia J. Khoury
    Vahid Shaygannejad
    Masoud Etemadifar
    Bhim Singhal
    Saloua Mrabet
    Matteo Foschi
    Mario Habek
    Nevin John
    Stella Hughes
    Pamela McCombe
    Radek Ampapa
    Anneke van der Walt
    Helmut Butzkueven
    Koen de Gans
    Chris McGuigan
    Celia Oreja-Guevara
    Maria Jose Sa
    Thor Petersen
    Talal Al-Harbi
    Angel Perez Sempere
    Bart Van Wijmeersch
    Nikolaos Grigoriadis
    Julie Prevost
    Orla Gray
    Journal of Neurology, 2024, 271 : 472 - 485
  • [6] How effective are disease-modifying drugs in delaying disability progression in relapsing-onset multiple sclerosis?
    Brown, M. G.
    Kirby, S.
    Skedgel, C.
    Fisk, J. D.
    Murray, T. J.
    Bhan, V.
    Sketris, I. S.
    JOURNAL OF NEUROLOGY, 2007, 254 : 55 - 55
  • [7] Progression independent of relapse activity is the main determinant of disability accumulation in relapsing-onset multiple sclerosis patients
    Portaccio, E.
    Bellinvia, A.
    Addazio, I.
    Betti, M.
    Ballerini, C.
    Pasto, L.
    Razzolini, L.
    Totaro, R.
    Spitaleri, D.
    Lugaresi, A.
    Cocco, E.
    Onofrj, M.
    Di Palma, F.
    Patti, F.
    Maimone, D.
    Valentino, P.
    Confalonieri, P.
    Protti, A.
    Sola, P.
    Lus, G.
    Maniscalco, G. T.
    Morra, V. Brescia
    Salemi, G.
    Granella, F.
    Pesci, I.
    Bergamaschi, R.
    Aguglia, U.
    Vianello, M.
    Simone, M.
    Lepore, V.
    Iaffaldano, P.
    Filippi, M.
    Trojano, M.
    Amato, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 440 - 442
  • [8] Olfactory threshold and odour identification are markers of disease activity in relapsing-onset multiple sclerosis
    Bsteh, Gabriel
    Lutterotti, Andreas
    Berger, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 56 - 57
  • [9] Risk of infection-related hospitalizations in people with primary-progressive relative to relapsing-onset multiple sclerosis
    Wijnands, Jose
    Hoegg, Tanja
    Zhu, Feng
    Kingwell, Elaine
    Zhao, Yinshan
    Fisk, John
    Ekuma, Okechukwu
    Evans, Charity
    Carruthers, Robert
    Marrie, Ruth-Ann
    Tremlett, Helen
    NEUROLOGY, 2016, 86
  • [10] Factors associated with the risk of secondary progression in multiple sclerosis
    Koch, M.
    Uyttenboogaart, M.
    van Harten, A.
    De Keyser, J.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (06) : 799 - 803